Skip to main content
TipRanks
Go Ultimate75% OFF

Sintx Technologies (1110) Q2 2026 Earnings Report

3 Followers

DE:1110 Q2 2026 EPS Results

Actual EPS
-EUR 0.67
Consensus EPS
-EUR 0.65
Beat/Miss
Missed by -EUR 0.02
One Year Ago EPS
-EUR 0.82

DE:1110 Q2 2026 Revenue Results

Actual Revenue
EUR 405.36K
Expected Revenue
EUR 412.53K
Beat/Miss
Missed by -EUR 7,174.431
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q2 2026
Date
08/11/2026
Time
After Close
Conference Call
Tuesday, August 11, 2026

Q2 2026 Earnings Call Audio

DE:1110 Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 11, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Neutral

The call conveyed meaningful commercial progress: strong year-over-year revenue and product revenue growth, higher gross profit and margins, significant purchase orders (> $3.2M), FDA clearance and first clinical use of the SiNAPTIC wedge, and access to additional financing. However, progress is tempered by persistent net losses, elevated operating cash burn, a low cash balance (~$3.6M), substantial doubt about going concern, increased working capital and G&A expenses, and uncertainty about the timing and conversion of announced orders into recognized revenue. The narrative is constructive on execution and go-to-market priorities but balanced by clear liquidity and execution risks.

Company Guidance

The company guided to total revenue of approximately $900,000–$1.1 million in Q3 2026 and approximately $1.0 million–$1.3 million in Q4 2026, noting that this outlook is subject to significant uncertainty around production timing, customer scheduling, manufacturing execution, and revenue recognition; as context, Q2 revenue was $452,000 (product revenue $447,000), up 199% YoY (product revenue +347%), with gross profit $278,000 and gross margin ~61.5%. Management highlighted liquidity and working-capital metrics including cash and cash equivalents of ~$3.6 million at June 30, stockholders’ equity of ~$4.8 million, inventory of $2.3 million (up from $1.0 million), net cash used in operating activities of $5.3 million for the first six months, and net loss of $2.7 million in Q2 ($5.5 million year-to-date); they also noted financing activity totaling roughly $5.0 million in gross proceeds (including ~$4.8 million net financing in H1), ~$1.3 million sold under the ATM with ~$5.1 million remaining capacity, and announced purchase orders aggregating in excess of $3.2 million that, if executed, would drive shipments and revenue into 2027.

  • Strong Quarter-over-Quarter Revenue GrowthTotal revenue of $452,000 in Q2 2026, up 199% from $151,000 in Q2 2025; product revenue of $447,000, up 347% from $100,000 a year ago.
  • Substantial Gross Profit and Margin ImprovementGross profit increased to $278,000 (up 388% year-over-year) and gross margin improved to ~61.5% compared with 37.7% in the prior year quarter, driven by higher-margin product sales, improved OEM pricing and favorable sales mix.
  • Meaningful Purchase Orders Provide Commercial VisibilityReceived purchase orders from multiple contract manufacturing customers with aggregate value exceeding $3.2 million; production and shipments have begun and are expected to continue into 2027 (recognition dependent on execution).
  • Regulatory and Early Commercial Milestones for SiNAPTICSiNAPTIC Foot & Ankle Osteotomy Wedge System received FDA 510(k) clearance (late 2025) and saw first U.S. clinical use in March 2026 with initial commercial revenue recognized during limited use review.
  • YTD Revenue and Product Revenue MomentumFor the first six months of 2026, total revenue was $832,000 (up 60% year-over-year) and product revenue increased 91% to $747,000; gross profit YTD was $422,000 versus $180,000 a year ago.
  • Access to Additional Capital During the QuarterCompleted financing transactions generating approximately $5 million in gross proceeds (June private placement and ATM sales); net cash provided by financing activities was $4.8 million in the first half of 2026, and $1.3 million has been sold under the ATM with ~$5.1 million remaining capacity.
  • Provided Near-Term Revenue GuidanceManagement expects Q3 2026 revenue of approximately $900,000 to $1.1 million and Q4 2026 revenue of approximately $1.0 million to $1.3 million, offering a roadmap tied to production and shipment timing.

DE:1110 Earnings History

DE:1110 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Nov 05, 20262026 (Q3)-0.28-0.22-3.193.06% (+2.89)
Aug 11, 20262026 (Q2)-0.65-0.67-0.8217.58% (+0.14)
Nov 13, 20252025 (Q3)-0.49-3.10-6.2350.22% (+3.13)
Mar 28, 20242023 (Q4)-0.39-0.04-15.7599.72% (+15.70)
Mar 30, 20232022 (Q4)-5.40-15.72-8.52-84.53% (-7.20)
Nov 22, 20222022 (Q3)-9.86-9.86-8.07-22.22% (-1.79)
Mar 25, 20222021 (Q4)-1614.25-1703.93-1165.85-46.15% (-538.08)
Mar 22, 20212020 (Q4)―-1165.85-13093.3491.10% (+11927.49)
Nov 16, 20202020 (Q3)―-1972.97-12196.5383.82% (+10223.56)
May 13, 20202020 (Q1)―-96.85-201.1151.84% (+104.25)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed